Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
COVID-19 bij patienten met immuungemedieerde inflammatoire aandoeningen
mei 2020 | Arthritis psoriatica, IBD, Psoriasis, RA, Spondyloartritis, Virale infecties